Disclosure Document for an 18 U

First Page		Document Content
Date: 2006-08-23 08:39:08 Heparins Breast cancer Protein-bound paclitaxel Paclitaxel Dalteparin sodium Abraxis BioScience Pulmonary embolism Deep vein thrombosis Venous thrombosis Medicine Chemistry Organic chemistry		Disclosure Document for an 18 U Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 11,19 KB Share Document on Facebook

	#3129 Predictive biomarker identification for response of vantictumab (OMP-18R5; anti-Frizzled) using primary patient-derived human pancreatic tumor xenografts Chun Zhang, Fiore Cattaruzza, Pete Yeung, Wan-Ching Yen, Ma DocID: 1pIzO - View Document
	High complete and partial response rate in a phase Ib/II pilot trial with albumin-bound paclitaxel and gemcitabine plus cisplatin in patients with advanced pancreatic cancer Jameson GS1, Borazanci E1, Poplin E2, Barrett DocID: 1osIl - View Document
	Patient Information ABRAXANE® (ah-BRAKS-ane) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) Read this Patient Information before you start receiving ABRAXANE and before each DocID: 1ltU6 - View Document
	Patient Information ABRAXANE® (ah-BRAKS-ane) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) Read this Patient Information before you start receiving ABRAXANE and before each DocID: 1lrvi - View Document
	My Treatment TRACKER For Advanced Pancreatic Cancer ABRAXANE® is a prescription DocID: 19HKt - View Document